Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - latanoprost, quantity: 50 microgram/ml; timolol maleate, quantity: 6.83 mg/ml (equivalent: timolol, qty 5 mg/ml) - eye drops, solution - excipient ingredients: dibasic sodium phosphate; monobasic sodium phosphate monohydrate; benzalkonium chloride; sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - reduction of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension who are insufficiently responsive to beta-blockers, prostaglandins or other intraocular pressure lowering medications. latanoprost/timolol eye drops should not be used to initiate therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - timolol maleate, quantity: 6.83 mg/ml (equivalent: timolol, qty 5 mg/ml); dorzolamide hydrochloride, quantity: 22.26 mg/ml (equivalent: dorzolamide, qty 20 mg/ml) - eye drops, solution - excipient ingredients: benzalkonium chloride; water for injections; sodium hydroxide; sodium citrate dihydrate; hyetellose; mannitol - the treatment of elevated intraocular pressure (iop) in patients with ocular hypertension or open-angle glaucoma when concomitant therapy is appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - timolol maleate, quantity: 6.83 mg/ml (equivalent: timolol, qty 5 mg/ml); dorzolamide hydrochloride, quantity: 22.26 mg/ml (equivalent: dorzolamide, qty 20 mg/ml) - eye drops, solution - excipient ingredients: sodium hydroxide; benzalkonium chloride; hyetellose; water for injections; mannitol; sodium citrate dihydrate - the treatment of elevated intraocular pressure (iop) in patients with ocular hypertension or open-angle glaucoma when concomitant therapy is appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - timolol maleate, quantity: 6.83 mg/ml (equivalent: timolol, qty 5 mg/ml); dorzolamide hydrochloride, quantity: 22.26 mg/ml (equivalent: dorzolamide, qty 20 mg/ml) - eye drops, solution - excipient ingredients: sodium citrate dihydrate; benzalkonium chloride; mannitol; hyetellose; sodium hydroxide; water for injections - the treatment of elevated intraocular pressure (iop) in patients with ocular hypertension or open-angle glaucoma when concomitant therapy is appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - timolol maleate, quantity: 6.83 mg/ml (equivalent: timolol, qty 5 mg/ml); dorzolamide hydrochloride, quantity: 22.26 mg/ml (equivalent: dorzolamide, qty 20 mg/ml) - eye drops, solution - excipient ingredients: hyetellose; sodium citrate dihydrate; mannitol; sodium hydroxide; benzalkonium chloride; water for injections - the treatment of elevated intraocular pressure (iop) in patients with ocular hypertension or open-angle glaucoma when concomitant therapy is appropriate.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - timolol maleate 3.4 mg/ml equivalent to timolol 2.5 mg/ml - eye drops, solution - 0.25% w/v - active: timolol maleate 3.4 mg/ml equivalent to timolol 2.5 mg/ml excipient: benzalkonium chloride dibasic sodium phosphate dodecahydrate disodium edetate dihydrate monobasic sodium phosphate dihydrate sodium chloride sodium hydroxide water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - timolol maleate 6.8 mg/ml equivalent to timolol 5 mg/ml - eye drops, solution - 0.5% w/v - active: timolol maleate 6.8 mg/ml equivalent to timolol 5 mg/ml excipient: benzalkonium chloride dibasic sodium phosphate dodecahydrate disodium edetate dihydrate monobasic sodium phosphate dihydrate sodium chloride sodium hydroxide water for injection

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol anhydrous 5 mg - timolol maleate tablets are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. timolol is indicated in patients who have survived the acute phase of myocardial infarction, and are clinically stable, to reduce cardiovascular mortality and the risk of reinfarction. timolol is indicated for the prophylaxis of migraine headache. timolol maleate is contraindicated in patients with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease (see warnings); sinus bradycardia; second- and third-degree atrioventricular block; overt cardiac failure (see warnings); cardiogenic shock; hypersensitivity to this product.

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol anhydrous 5 mg - timolol maleate tablets are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. timolol is indicated in patients who have survived the acute phase of myocardial infarction, and are clinically stable, to reduce cardiovascular mortality and the risk of reinfarction. timolol is indicated for the prophylaxis of migraine headache. timolol maleate is contraindicated in patients with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease (see warnings); sinus bradycardia; second- and third-degree atrioventricular block; overt cardiac failure (see warnings); cardiogenic shock; hypersensitivity to this product.

United States - English - NLM (National Library of Medicine)

sandoz inc - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol anhydrous 5 mg in 1 ml - timolol gfs 0.25% and 0.5% are indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol gfs is contraindicated in patients with: • bronchial asthma • history of bronchial asthma • severe chronic obstructive pulmonary disease • sinus bradycardia • second or third degree atrioventricular block • overt cardiac failure • cardiogenic shock • hypersensitivity to any component of this product. teratogenic effects pregnancy category c: teratogenicity studies with timolol in mice, rats, and rabbits at oral doses up to 50 mg/kg/day (7,000 times the systemic exposure following the maximum recommended human ophthalmic dose) demonstrated no evidence of fetal malformations. although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring. doses of 1,000 mg/kg/day (142,000 times the systemic exposure following the maximum recommended human ophthalmic dose) were maternotoxic in